A group of Italian researchers has requested compassionate use in Europe from Revolution Medicine for daraxonrasib, a drug that doubles survival in patients with metastatic pancreatic cancer. The petition seeks to allow affected individuals to access the treatment before its official approval, through specialized centers. The goal is clear: to expedite access to save lives.
How daraxonrasib works at the molecular level 🧬
Daraxonrasib is a selective inhibitor of KRAS G12D, a mutation present in a significant percentage of pancreatic adenocarcinomas. The compound blocks the mutated protein, interrupting cell proliferation signals. Clinical trials show a median overall survival that doubles that of standard treatments, with a manageable toxicity profile. The compassionate use pathway would allow for collecting additional efficacy data in real-world conditions.
The drug that arrives late but in a hurry (and without paperwork) ⏳
While health authorities take their time to approve the medication, patients watch the calendar like someone waiting for a train that never arrives. The Italian researchers have decided to knock on Revolution Medicine's door with a clear message: give it to us now, because we don't have time for bureaucracy. At least, the compassionate use pathway avoids having to wait for a committee to decide if the drug is good enough to save lives.